HK1205253A1 - Detection and treatment of cd30 cancers cd30 - Google Patents
Detection and treatment of cd30 cancers cd30Info
- Publication number
- HK1205253A1 HK1205253A1 HK15105475.6A HK15105475A HK1205253A1 HK 1205253 A1 HK1205253 A1 HK 1205253A1 HK 15105475 A HK15105475 A HK 15105475A HK 1205253 A1 HK1205253 A1 HK 1205253A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancers
- detection
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597547P | 2012-02-10 | 2012-02-10 | |
PCT/US2013/025392 WO2013119990A2 (en) | 2012-02-10 | 2013-02-08 | Detection and treatment of cd30+ cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1205253A1 true HK1205253A1 (en) | 2015-12-11 |
Family
ID=48948166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15105475.6A HK1205253A1 (en) | 2012-02-10 | 2015-06-09 | Detection and treatment of cd30 cancers cd30 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10444241B2 (ja) |
EP (2) | EP3575794A1 (ja) |
JP (4) | JP6602012B2 (ja) |
CN (2) | CN108324943B (ja) |
AU (1) | AU2013216863B2 (ja) |
CA (1) | CA2864092C (ja) |
ES (1) | ES2725569T3 (ja) |
HK (1) | HK1205253A1 (ja) |
WO (1) | WO2013119990A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2864092C (en) | 2012-02-10 | 2021-06-29 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
CN108474793A (zh) * | 2015-10-30 | 2018-08-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 预后方法 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2734287C2 (de) | 1977-07-29 | 1983-02-10 | Manfred 7250 Leonberg Luik | Gerät zum Reinigen von Gegenständen, insbesondere Zahnprothesen |
EP0000877B1 (de) | 1977-08-31 | 1983-05-18 | Grisebach, Hans-Theodor | Manipulator zum Positionieren von Werkstücken oder anderen Lasten |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
DK0627940T3 (da) | 1992-03-05 | 2003-09-01 | Univ Texas | Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ATE311895T1 (de) * | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
ES2201097T3 (es) | 1994-01-31 | 2004-03-16 | Trustees Of Boston University | Bibliotecas de anticuerpos policlonales. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
CN1312181C (zh) * | 2001-02-12 | 2007-04-25 | 米德列斯公司 | 抗Fcα受体(CD89)的人单克隆抗体 |
CA2446806A1 (en) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
JPWO2003000286A1 (ja) * | 2001-06-22 | 2004-10-07 | 第一サントリーファーマ株式会社 | 好酸球増多性疾患治療薬 |
CN1638800B (zh) * | 2002-01-09 | 2014-07-16 | 梅达雷克斯有限责任公司 | 抗cd30的人类单克隆抗体 |
WO2003104432A2 (en) * | 2002-06-07 | 2003-12-18 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
EP1725249B1 (en) | 2003-11-06 | 2014-01-08 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7790160B2 (en) * | 2004-10-01 | 2010-09-07 | Medarex, Inc. | Method of treating CD30 positive lymphomas |
EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
CA2587589A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
ES2498794T3 (es) * | 2005-02-18 | 2014-09-25 | Medarex, L.L.C. | Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
EP1917020B1 (en) | 2005-07-07 | 2016-05-25 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
CA2616005C (en) | 2005-07-18 | 2015-09-22 | Seattle Genetics, Inc. | Beta-glucuronide-linker drug conjugates |
WO2007044616A2 (en) | 2005-10-06 | 2007-04-19 | Xencor, Inc. | Optimized anti-cd30 antibodies |
US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
WO2008041594A1 (fr) * | 2006-09-26 | 2008-04-10 | Olympus Corporation | procÉdÉ d'analyse de la sensibilitÉ À un mÉdicament À base d'anticorps |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2099823B2 (en) | 2006-12-01 | 2022-02-09 | Seagen Inc. | Variant target binding agents and uses thereof |
WO2009048967A1 (en) * | 2007-10-12 | 2009-04-16 | Seattle Genetics, Inc. | Combination therapy with antibody-drug conjugates |
SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
NO2842575T3 (ja) | 2008-03-18 | 2018-02-24 | ||
EP3545969B1 (en) | 2009-01-09 | 2023-12-13 | Seagen Inc. | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
EP3260470A1 (en) | 2010-03-05 | 2017-12-27 | The John Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
CA2864092C (en) | 2012-02-10 | 2021-06-29 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
-
2013
- 2013-02-08 CA CA2864092A patent/CA2864092C/en active Active
- 2013-02-08 EP EP19168115.4A patent/EP3575794A1/en not_active Withdrawn
- 2013-02-08 ES ES13746038T patent/ES2725569T3/es active Active
- 2013-02-08 AU AU2013216863A patent/AU2013216863B2/en active Active
- 2013-02-08 CN CN201810293746.4A patent/CN108324943B/zh active Active
- 2013-02-08 US US14/376,957 patent/US10444241B2/en active Active
- 2013-02-08 WO PCT/US2013/025392 patent/WO2013119990A2/en active Application Filing
- 2013-02-08 CN CN201380009027.0A patent/CN104254778A/zh active Pending
- 2013-02-08 JP JP2014556742A patent/JP6602012B2/ja active Active
- 2013-02-08 EP EP13746038.2A patent/EP2812702B1/en active Active
-
2015
- 2015-06-09 HK HK15105475.6A patent/HK1205253A1/xx unknown
-
2018
- 2018-03-14 JP JP2018046117A patent/JP6744885B2/ja active Active
-
2019
- 2019-09-13 US US16/571,035 patent/US11366118B2/en active Active
-
2020
- 2020-03-30 JP JP2020059264A patent/JP7026158B2/ja active Active
-
2022
- 2022-02-14 JP JP2022020085A patent/JP2022070958A/ja active Pending
- 2022-05-18 US US17/747,591 patent/US20220373553A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6744885B2 (ja) | 2020-08-19 |
JP2018109645A (ja) | 2018-07-12 |
JP2020122793A (ja) | 2020-08-13 |
WO2013119990A3 (en) | 2014-10-16 |
CA2864092A1 (en) | 2013-08-15 |
US20220373553A1 (en) | 2022-11-24 |
JP7026158B2 (ja) | 2022-02-25 |
CN108324943B (zh) | 2024-03-08 |
EP2812702B1 (en) | 2019-04-17 |
AU2013216863A1 (en) | 2014-08-28 |
JP2015510125A (ja) | 2015-04-02 |
ES2725569T3 (es) | 2019-09-24 |
EP3575794A1 (en) | 2019-12-04 |
CA2864092C (en) | 2021-06-29 |
JP6602012B2 (ja) | 2019-11-06 |
US20200110091A1 (en) | 2020-04-09 |
WO2013119990A2 (en) | 2013-08-15 |
US10444241B2 (en) | 2019-10-15 |
US20140377286A1 (en) | 2014-12-25 |
EP2812702A4 (en) | 2015-11-04 |
EP2812702A2 (en) | 2014-12-17 |
AU2013216863B2 (en) | 2018-09-06 |
JP2022070958A (ja) | 2022-05-13 |
CN104254778A (zh) | 2014-12-31 |
US11366118B2 (en) | 2022-06-21 |
CN108324943A (zh) | 2018-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276300A (en) | GRPR antagonists for the detection, diagnosis and treatment of GRPR-positive cancer | |
HK1212273A1 (en) | Treatment and diagnosis of melanoma | |
EP2890815A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
HRP20170225T1 (hr) | Fosfoplatini i njihova uporaba za liječenje karcinoma | |
GB2500588B (en) | Systems and methods of hyperthermal treatment | |
HK1214128A1 (zh) | 癌症的治療 | |
HK1215000A1 (zh) | 結腸癌的治療和診斷 | |
HK1205254A1 (en) | Methods of treatment of cancer | |
GB201217892D0 (en) | Treatment of cancer | |
HK1204956A1 (en) | Treatment of cancer | |
SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
GB201412831D0 (en) | Detection and treatment of breast cancer | |
HK1205253A1 (en) | Detection and treatment of cd30 cancers cd30 | |
GB201213968D0 (en) | Prevention and treatment of osteoarthritis | |
GB201217890D0 (en) | Treatment of cancer | |
GB201317373D0 (en) | Treatment and prevention of cancer | |
GB201301685D0 (en) | Diagnosis and treatment of cancer | |
GB201303115D0 (en) | Detection and treatment of liver cancer | |
GB201222949D0 (en) | Combination Treatment of Cancer | |
GB201222950D0 (en) | Combination treatment of cancer | |
GB201208296D0 (en) | Treatment of cancer | |
GB201202081D0 (en) | Prevention and/or treatment of cancer and/or cancer metastasis | |
GB201221118D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment |